StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research note released on Saturday. The firm issued a sell rating on the stock.
Moleculin Biotech Stock Performance
Shares of MBRX opened at $2.40 on Friday. The company’s fifty day moving average is $3.41 and its 200 day moving average is $5.20. Moleculin Biotech has a fifty-two week low of $2.12 and a fifty-two week high of $15.75.
Institutional Investors Weigh In On Moleculin Biotech
An institutional investor recently bought a new position in Moleculin Biotech stock. Armistice Capital LLC acquired a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 3,207,417 shares of the company’s stock, valued at approximately $2,753,000. Armistice Capital LLC owned about 9.60% of Moleculin Biotech as of its most recent SEC filing. Hedge funds and other institutional investors own 15.52% of the company’s stock.
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Featured Stories
- Five stocks we like better than Moleculin Biotech
- Pros And Cons Of Monthly Dividend Stocks
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- 2 Option Strategies to Maximize Profits in a Bear Market
- Short Selling: How to Short a Stock
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.